For example, the combination of the MEK inhibitor cobimetinib and the BRAF inhibitor vemurafenib is used to treat patients with melanoma induced by BRAF proteins carrying V600E or V600K mutations.465 The combination of ATRA and ATO has a synergistic effect, which can improve treatment outcomes for acute promyelocytic leukemia and reduce the development of drug resistance.466 In the context of immunotherapy combinations, significant advancements have been made. The gene discussed is BRAF; the disease is acute promyelocytic leukemia.